LinkedIn video ad examples

💡 Des processus efficaces, moins d’effort, plus de temps pour vos client·e·s. 💡 Avec nos solutions easy pour les soins, vous gagnez un temps précieux. 👉 Découvrez dès maintenant comment nos solutions font la différence.

Introducing IPS e.max ZirCAD Prime — a game-changer in CAD/CAM dentistry that combines ultra-fast sintering (just 15 minutes), impressive flexural strength (1,100 MPa), and a beautifully natural gradient of translucency. This block offers: • A streamlined chairside workflow (save time). • Reliable mechanical performance (thin walls down to 0.8 mm). • Esthetic results that your patients will love. Ready to see it in action? Claim your free sample today and experience what true speed + strength looks like in your dental practice. Let’s elevate your restorative workflow — faster, stronger, smarter.

The Mass Spectrometry Facility supports researchers in translating complex biological samples into high-quality molecular data. The facility provides bottom-up proteomics, interactomics, consultations, data analysis and custom method development. Its advanced instrumentation enables high-resolution analysis of proteins and other biomolecules, supports studies based on limited sample material, and helps generate actionable insights for biomedical research. From experimental design to data acquisition and interpretation, the team works with researchers to build workflows adapted to the scientific question. IN-MOL-CELL Infrastructure is funded by the European Union - NextGenerationEU under the National Recovery and Resilience Plan. IN-MOL-CELL Infrastructure is also funded by the European Union under Horizon Europe, Project 101059801 - RACE, and by the RACE-PRIME project carried out within the IRAP programme of the Foundation for Polish Science, co-financed by the European Union under the European Funds for Smart Economy 2021-2027. #IIMCB #INMOLCELL #MassSpectrometry #Proteomics #Interactomics #Multiomics #MolecularBiology #ResearchInfrastructure #NextGenerationEU, #FunduszeUE

The Preclinical Drug Development Facility provides an integrated workflow from gene cloning to high-resolution protein structure determination. The facility supports protein production in bacterial, mammalian and insect expression systems, recombinant protein purification, crystallization of proteins and their complexes, X-ray data analysis, and cryo-electron microscopy from sample preparation to 3D structure. Its work helps researchers understand molecular mechanisms, support drug discovery projects and move from concept to structural insight. By combining protein production, cryo-EM, crystallography and expert consultation, the facility supports structural and functional studies across molecular and biomedical research. IN-MOL-CELL Infrastructure is funded by the European Union - NextGenerationEU under the National Recovery and Resilience Plan. IN-MOL-CELL Infrastructure is also funded by the European Union under Horizon Europe, Project 101059801 - RACE, and by the RACE-PRIME project carried out within the IRAP programme of the Foundation for Polish Science, co-financed by the European Union under the European Funds for Smart Economy 2021-2027. #IIMCB #INMOLCELL #PreclinicalDrugDevelopment #ProteinScience #StructuralBiology #CryoEM #XrayCrystallography #DrugDiscovery #MolecularBiology #ResearchInfrastructure #KorzyściDlaCiebie, #NextGenerationEU, #FunduszeUE

🔬Verbreed uw kennis als voedingsdeskundige! Duik in de wereld van lichaamssamenstelling analyse.

Estudante de Enfermagem com formação prevista para dez/2027? O Programa de Estágio Assistencial 2027 está com inscrições abertas!

Inicie sua carreira em Enfermagem ao lado de profissionais experientes. Estágio assistencial 2027 no Hospital Alemão Oswaldo Cruz.

II COBBIND 2026: encontros, inovação e muitos motivos para celebrar! A Infors HT esteve presente em mais uma importante edição do Congresso Brasileiro de Biotecnologia Industrial, o COBBIND, realizada em Campos do Jordão/SP, compartilhando conhecimento, fortalecendo conexões e acompanhando de perto as tendências e os avanços que estão ajudando a construir o futuro da biotecnologia. E, em meio a tantos encontros e conexões, tivemos também um momento especial para celebrar: durante o happy hour, brindamos aos 10 anos da Infors HT na América Latina e no Brasil! Uma década de história construída com inovação, tecnologia, parcerias e, principalmente, pessoas que fazem parte dessa trajetória. Agradecemos a todos os clientes, parceiros, colaboradores e amigos que estiveram conosco e ajudaram a tornar esse momento ainda mais especial.Seguimos juntos, celebrando a nossa história e construindo os próximos capítulos! #InforsHT #InforsLatam #COBBIND2026 #Biotecnologia #InforsHTLatam

Integrated Rehab is looking for Physical Therapists & PTAs! Join a collaborative team that values continued education, quality patient care and professional growth. Apply today!

We're honored the leadership and care team at Modena Reserve Bethesda, a Solera Senior Living community, were willing to share stories on how Inspiren continues to shape the way they provide care. "We are able to use the two-way voice feature and just explain to them that we are on our way. So that has reduced a lot of anxiety." — Beatrice Adhiambo, Resident Services Director Two-Way Voice is live and already changing how communities like Modena Reserve Bethesda respond to eCall alerts. We'd love for you to hear it from them. #SeniorLiving #AssistedLiving #eCall

Embrace the Case. - 60-year-old female - Right renal angiomyolipoma, 4.6 cm - Focal and encapsulated Treated with Embrace® HES. - 44% diameter reduction at 30 days - 45% diameter reduction at 90 days - No revascularization - No local tumor progression Conclusion: Embolization of a renal angiomyolipoma with Embrace® HES achieved technical success with sustained tumor control. No evidence of local progression or recanalization at 30 or 90 days. View the Full Case: https://lnkd.in/gNgniAed #EmbraceHES #Instylla #InterventionalRadiology #Embolization #IR #InterventionalOncology #RenalAngiomyolipoma

In the Instylla HES Hypervascular Tumor Study, there was no clinically significant non-target embolization associated with Embrace® HES in 148 treated vessels. Proven in a prospective, randomized, multicenter pivotal trial. #EmbraceHES #InterventionalRadiology #Embolization #IR #ClinicalData

Precision medicine already works. The harder problem is making it accessible. At FutureHealth․Now 2026, Fabio La Mola, Partner at Bain & Company, reflected on the progress made over the past two decades, while highlighting the challenges that remain, from treatment gaps to affordability and access. #IHHHealthcare #CareForGood #FutureHealthNow

We are living longer than ever. The real challenge is helping people live those extra years in good health. Speaking at FutureHealth․Now 2026, Dr Zubin Daruwalla, Group Director of the Technology Innovation Office at National University Health System, shared his vision for closing that gap: healthcare that is proactive, predictive and personalised, with investments that improve outcomes for the many, not just a select few. #IHHHealthcare #CareForGood #FutureHealthNow

A decade of clinical AI leadership. Another record-performing quarter. A clear trajectory toward doubling revenue. Ibex Medical Analytics is proud to celebrate 10 years of pioneering clinical innovation. But we aren't just reflecting on a decade of validation—we are accelerating forward. Ahead of the European Congress of Pathology (ECP) 2026, we are thrilled to announce the release of Ibex Lymph Node (RUO). This milestone completes the industry’s most comprehensive, clinical-grade Breast AI Suite. Digital laboratories now have a unified workspace designed to combat severe pathologist shortages, mounting workloads, and increasingly complex cases, seamlessly transitioning across: Biopsy & excision review (H&E), standardized IHC scoring (including HER2, ER, PR, and Ki67) and advanced metastases detection in lymph nodes Our strong commercial momentum is also driving a natural expansion into biopharma. We are leveraging this proven, clinical-grade foundation to expand our partnerships with leading pharmaceutical organizations, helping to accelerate biomarker discovery and drug development to bring targeted therapies to patients faster. Heading to #ECP2026? Come celebrate 10 years of pathology innovation with the Ibex team, explore our unmatched clinical evidence, and see the completed Breast AI Suite in action at Booth #330! Read the full announcement here: https://lnkd.in/exFXf9Cs #DigitalPathology #PrecisionOncology #Biopharma #ClinicalAI #ECP2026 #HealthTech

What does it look like to bring primary care directly to patients at home? Spend a shift with Olivia Richman, MD, as she provides care to patients who may have difficulty accessing traditional office-based care. At Intention Health Care, our house calls program brings physicians directly into the home, helping patients access ongoing medical care, diagnostics, and coordinated support where they are most comfortable. Come along for a look at Dr. Richman's day and the impact of meeting patients where they are. Learn more at intentionhealthcare.com #CareCoordination #IntentionHealthCare #ImprovedPatientOutcomes #PhysicianLeadCare

Following the success of our previous Dawes Redman® webinar, we’re excited to announce that Dr Becky Liu will be returning for another session. Based on your feedback, ‘Mastering the Dawes Redman® Antenatal Interpretation Tool: A Deeper Dive into Clinical Dilemmas’ will focus on applying the analysis to more complex real-world cases. But what is the Dawes Redman® analysis from Huntleigh? And what are the benefits? Here’s Dr Liu’s summary of the analysis from the first webinar. Join us on the 6th of October for more insights from Dr Liu in 'Mastering the Dawes Redman® Antenatal Interpretation Tool: A Deeper Dive into Clinical Dilemmas'.

Personalized HCP engagement is a key theme at Fierce Pharma Week, but how do you know what to do next? Fresh from her session on HCP Velocity, Caroline Lustig from Inizio Medical explains how understanding where an HCP is in their journey, and the drivers and barriers that got them there, can help teams identify the next best action and anticipate meaningful movement. Ultimately, it's about giving teams greater clarity around where to prioritize engagement and investment. Hear Caroline’s take 👇 #FPW2026 #FiercePharmaWeek #IntelligentCommercialization

How can you spot when a launch is drifting, and respond before it’s too late? Yesterday at #FiercePharmaWeek, Hokan Lars Ojert and Isabelle Amick, PhD, Inizio Engage, took to the stage to explore how Intelligent Commercialization™ can help turn launch strategy into launch success. Following their talk, they shared how bringing together qualitative insight and quantitative data can help teams spot leading indicators, respond quickly and put those insights into practice throughout the launch cycle. Hear their key takeaways below 👇 #FPW2026 #Commercialization #Pharma #IntelligentCommercialization

Next Wednesday (9/16), BiopharmaWebinars is hosting two talks on the gap between collecting process data and actually being able to use it for monitoring, decision-making, and AI. Jack Prior (Sanofi) on BioMetre, his maturity framework for process monitoring readiness: how 25+ products scored on it, and the pattern across them. Masaki Yamada (Invert) on the AI agents we build for routine bioprocess decisions, like deviations, batch comparisons, tech transfers, and regulatory justifications. Excited to see everyone there! Can't make it live? Register anyway and the recording comes to you. 9:30am ET / 6:30am PT / 2:30pm BST / 3:30pm CEST Register: https://lnkd.in/gsV5vCkB

We're proud of what we've built – and even more excited about what we're building next. Over the past year, we've continued to grow with one simple goal: backing Australians to take care of their health and care. Behind every consultation, innovation and milestone is an incredible team. Our doctors are at the heart of everything we do, supported by a strong culture of collaboration and an unwavering commitment to clinical governance, quality and safety. These aren't just words; they're the foundations of every decision we make. A huge thank you to our team, our clinicians, our partners and, most importantly, the millions of Australians who trust us with their care. We're incredibly proud of how far we've come and excited for what's ahead. #DigitalHealth #Healthcare #Telehealth #ClinicalExcellence #Teamwork

Upgrade your CMS MA Star Ratings with STARSTrack!

Struggling with CMS MA Star ratings? StarsTrack helps plans identify improvement areas and provide actionable insights to drive better outcomes.

The HoverMatt® PROS™ (Patient Repositioning Off-Loading System) portfolio of air and non-air breathable, wipeable matts are used to safely reposition (including boosting and turning), transfer, and prone patients to reduce patient and caregiver injuries. Link feature reduces boosting frequency and device migration and promotes caregiver safety by reducing pull force by 90%.